NCT04091113 (HAEKA) is a clinical trial in Hereditary Angioedema, sponsored by CENTOGENE GmbH Rostock.

Who is sponsoring NCT04091113?

NCT04091113 is sponsored by CENTOGENE GmbH Rostock.

What condition does NCT04091113 study?

NCT04091113 studies Hereditary Angioedema.

Is NCT04091113 still recruiting?

NCT04091113 is currently terminated. Last updated 10 March 2022.

Last reviewed 2022-03-10 · How we verify

NCT04091113: HAEKA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hereditary Angioedema Kininogen Assay

Terminated Last updated 10 March 2022

What this trial tests

trial in Hereditary Angioedema in 59 participants. Terminated before completion.

Timeline

1 September 2019

Primary endpoint
12 September 2021

31 December 2021

Quick facts

Lead sponsor	CENTOGENE GmbH Rostock
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	59
Start date	1 September 2019
Primary completion	12 September 2021
Estimated completion	31 December 2021
Sites	7 locations across Germany

Conditions studied

Hereditary Angioedema — all drugs for Hereditary Angioedema →

Sponsor

CENTOGENE GmbH Rostock

Who can join

18 and older, any sex, with Hereditary Angioedema. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A multicenter epidemiological observational study aiming to explore the cleaved high-molecular weight kininogen (cHMWK) including identification and characterization of other metabolite/biomarkers in HAE type 1/2 patients

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hereditary Angioedema

Currently open trials in the same condition.

NCT06960213 — STOP-HAE: A Phase 3 Study of ADX-324 in HAE · Phase 3 · recruiting
NCT06806657 — Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab · Phase 4 · recruiting
NCT06573723 — Institutional Registry of Rare Diseases · recruiting
NCT05691361 — Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients · Phase 1, PHASE2 · active not recruiting
NCT05505916 — An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angio · Phase 3 · active not recruiting

Other CENTOGENE GmbH Rostock trials

Trials by the same sponsor.

NCT06040008 — Investigating the Impact of Environmental Factors on the Transcriptomics Profile in Healthy Individuals · completed
NCT05075187 — Epidemiological Study in FRONtoTemporal Dementia · completed
NCT04925804 — Unraveling Genetics of HypoPhosPhatasia (HPP Genetics) · completed
NCT04548921 — Biomarker for Friedreich's Ataxia (BioFridA) · unknown
NCT03866590 — Pyruvate Kinase Deficiency Epidemiological Study (PIECE) · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04091113 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CENTOGENE GmbH Rostock
Last refreshed: 10 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04091113.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing